Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease.
Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. Palmieri A, et al. Eur Urol. 2009 Aug;56(2):363-9. doi: 10.1016/j.eururo.2009.05.012. Epub 2009 May 18. Eur Urol. 2009. PMID: 19473751 Clinical Trial.
BACKGROUND: Extracorporeal shock wave therapy (ESWT) is a conservative therapy for patients with Peyronie's disease (PD). OBJECTIVE: To investigate the effects of ESWT in patients with PD. DESIGN, SETTING, AND PARTICIPANTS: …
BACKGROUND: Extracorporeal shock wave therapy (ESWT) is a conservative therapy for patients with Peyronie …
Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled clinical trial.
Sakr AM, Fawzi AM, Kamel M, Ali MM. Sakr AM, et al. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):93-99. doi: 10.1038/s41391-021-00464-8. Epub 2021 Oct 11. Prostate Cancer Prostatic Dis. 2022. PMID: 34635804 Clinical Trial.
Patients were randomized into two groups: a verum treatment group and a placebo treatment group. Patients of verum group in the lithotomy position received a perineally applied ESWT treatment once a week for four weeks with 3000 impulses each. P …
Patients were randomized into two groups: a verum treatment group and a placebo treatment group. Patients of ver …